Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) EBIT Margin (2019 - 2025)

Keros Therapeutics (KROS) has disclosed EBIT Margin for 6 consecutive years, with 7702.63% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 1818570.0% year-over-year to 7702.63%, compared with a TTM value of 27.71% through Dec 2025, down 25398795.0%, and an annual FY2025 reading of 27.71%, changed N/A over the prior year.
  • EBIT Margin was 7702.63% for Q4 2025 at Keros Therapeutics, down from 109.34% in the prior quarter.
  • Across five years, EBIT Margin topped out at 1576900.0% in Q1 2021 and bottomed at 541000.0% in Q3 2023.
  • Average EBIT Margin over 5 years is 59926.21%, with a median of 176.6% recorded in 2025.
  • The sharpest move saw EBIT Margin tumbled -157703403bps in 2022, then surged 52588222bps in 2024.
  • Year by year, EBIT Margin stood at 27.18% in 2021, then surged by 728bps to 170.71% in 2022, then tumbled by -19130bps to 32486.01% in 2023, then soared by 132bps to 10483.07% in 2024, then plummeted by -173bps to 7702.63% in 2025.
  • Business Quant data shows EBIT Margin for KROS at 7702.63% in Q4 2025, 109.34% in Q3 2025, and 219.16% in Q2 2025.